Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) Amortization of Deferred Charges (2017 - 2020)

Forte Biosciences (FBRX) has disclosed Amortization of Deferred Charges for 4 consecutive years, with $654000.0 as the latest value for Q1 2020.

  • On a quarterly basis, Amortization of Deferred Charges rose 360.56% to $654000.0 in Q1 2020 year-over-year; TTM through Mar 2020 was $2.2 million, a 91.18% increase, with the full-year FY2019 number at $1.7 million, up 46.25% from a year prior.
  • Amortization of Deferred Charges was $654000.0 for Q1 2020 at Forte Biosciences, up from $57000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $1.4 million in Q3 2019 to a low of $57000.0 in Q4 2019.
  • A 4-year average of $315615.4 and a median of $147000.0 in 2017 define the central range for Amortization of Deferred Charges.
  • Biggest YoY gain for Amortization of Deferred Charges was 847.55% in 2019; the steepest drop was 80.17% in 2019.
  • Forte Biosciences' Amortization of Deferred Charges stood at $149000.0 in 2017, then fell by 2.68% to $145000.0 in 2018, then plummeted by 60.69% to $57000.0 in 2019, then surged by 1047.37% to $654000.0 in 2020.
  • Per Business Quant, the three most recent readings for FBRX's Amortization of Deferred Charges are $654000.0 (Q1 2020), $57000.0 (Q4 2019), and $1.4 million (Q3 2019).